Skip to content
Beakers

ENSEM Therapeutics Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets.

ENSEM Therapeutics Inc. (ENSEM), a Boston-based biotechnology company focusing on high value and difficult-to-drug oncology targets, announced today the closing of a series A2 financing.

Back To Top
Search